Tradestie Institutional Equity Comparison Engine

SYRE vs CGON โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SYRE Overall Edge

SYRE Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical while CGON counters with relative strength in Options & Structure. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SYRE N/M vs CGON N/M Fwd P/E
Growth & Margin Winner SYRE
Op Margin 0.0% vs -4293.5% ยท YoY +0.0% vs -3.7%
Momentum & Technical Winner SYRE
1Y +341.7% vs +125.0% ยท 52W Pos 88% vs 84%
Options & Structure Winner CGON
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (85th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
1M Return +41.93%
1Y Return +124.96%
Forward P/E N/M
Unified AI Score
44.5 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% CGON +124.96% Spread: +216.78 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% CGON TTM Op. Margin: -4293.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs CGON. Trailing 12-month operating profitability (SYRE 0.0% vs CGON -4293.5%) and valuation multiples (SYRE N/M vs CGON N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (5) vs CGON (2)
Institutional Metric SYRE CGON Criterion Row Winner
Market Capitalization Scale $9.8B $6.3B Larger Scale SYRE
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -3.7% Higher Growth SYRE
Operating Margin (TTM) Profitability 0.0% -4293.5% Higher Margin SYRE
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -35.0% -28.3% Higher ROE CGON
52-Week Range Position Momentum 88% ($22โ€“$111) 84% ($37โ€“$94) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 0.75ฮฒ ยท 89% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 44.5 / 100 (HOLD) Higher Composite CGON

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs CGON Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor CGON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.